Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Kura Oncology (NASDAQ:KURA) hosted an analyst/investor event showcasing preclinical data for its farnesyl transferase inhibitor (FTI) program, specifically highlighting KO-2806 (darlifarnib). The data demonstrates the potential of FTIs to overcome drug resistance when combined with PI3Kα inhibitors, KRAS inhibitors, and antiangiogenic tyrosine kinase inhibitors (TKIs) across multiple tumor types.
The company's next-generation FTI, KO-2806, shows superior potency and enhanced properties compared to first-generation candidates. Preclinical studies revealed that FTIs effectively suppress mTOR signaling and demonstrate the potential to impact over 200,000 incident patients annually in the U.S. across various cancers including renal cell carcinoma, neuroendocrine tumors, NSCLC, colorectal cancer, and breast cancer.
Preliminary clinical data for KO-2806 will be presented at the ESMO Congress 2025 in October, with three scheduled presentations.
Kura Oncology (NASDAQ:KURA) ha organizzato un evento per analisti/investitori presentando dati preclinici sul suo inibitore della farnesil transferase (FTI), con particolare attenzione a KO-2806 (darlifarnib). I dati evidenziano il potenziale degli FTI nel superare la resistenza ai farmaci quando combinati con inibitori PI3Kα, inibitori KRAS e inibitori tirosina chinasi antiangiogenici (TKI) in diversi tipi di tumore.
L’FTI di prossima generazione dell’azienda, KO-2806, mostra potenza superiore e proprietà migliorate rispetto ai candidati di prima generazione. Studi preclinici hanno rivelato che gli FTI sopprimono efficacemente la segnalazione mTOR e hanno il potenziale per impattare oltre 200.000 pazienti incidenti all’anno negli Stati Uniti in vari tumori tra cui carcinoma renale, tumori neuroendocrini, NSCLC, cancro del colon-retto e cancro al seno.
Dispositivi clinici preliminari per KO-2806 saranno presentati all’ESMO Congress 2025 in ottobre, con tre presentazioni previste.
Kura Oncology (NASDAQ:KURA) organizó un evento para analistas/inversores donde se presentaron datos preclínicos sobre su inhibidor de la transferasa de farnesilo (FTI), destacando especialmente KO-2806 (darlifarnib). Los datos muestran el potencial de los FTI para superar la resistencia a fármacos cuando se combinan con inhibidores de PI3Kα, inhibidores de KRAS e inhibidores tirosina quinasa antiangiogénicos (TKI) en varios tipos de tumor.
El FTI de próxima generación de la compañía, KO-2806, demuestra mayor potencia y propiedades mejoradas en comparación con los candidatos de primera generación. Los estudios preclínicos revelaron que los FTI inhiben eficazmente la señalización mTOR y muestran el potencial de impactar a más de 200,000 pacientes incidentes al año en EE. UU. en varios cánceres, incluidos carcinoma de células renales, tumores neuroendocrinos, NSCLC, cáncer colorrectal y cáncer de mama.
Los datos clínicos preliminares de KO-2806 se presentarán en el Congreso ESMO 2025 en octubre, con tres presentaciones programadas.
Kura Oncology(NASDAQ:KURA)가 분석가/투자자 행사를 주최하여 파네실 전달효소 억제제(FTI) 프로그램에 대한 전임상 데이터를 공개했고, 특히 KO-2806(다르피나비)를 강조했습니다. 데이터는 FTI가 PI3Kα 억제제, KRAS 억제제 및 항혈관생성 타이로신 키나아제 억제제(TKI)와의 병용 시 여러 종양에서 약물 저항성을 극복할 수 있는 가능성을 보여줍니다.
차세대 FTI인 KO-2806는 1세대 후보들에 비해 우수한 효능과 향상된 특성을 보여줍니다. 전임상 연구에 따르면 FTI는 mTOR 신호 전달을 효과적으로 억제하고 다양한 암(신장 세포 암종, 신경내분비 종양, NSCLC, 직결장암, 유방암 등)에서 미국 내 연간 20만 명이 넘는 신규 환자에 영향을 줄 수 있는 잠재력이 있습니다.
KO-2806의 예비 임상 데이터는 10월에 열리는 ESMO Congress 2025에서 발표될 예정이며, 세 건의 발표가 예정되어 있습니다.
Kura Oncology (NASDAQ:KURA) a organisé un événement pour analystes/investisseurs présentant des données précliniques sur son inhibiteur de transférase de farnétylation (FTI), en mettant particulièrement en avant KO-2806 (darlifarnib). Les données démontrent le potentiel des FTI pour surmonter la résistance aux médicaments lorsqu’ils sont combinés avec des inhibiteurs PI3Kα, des inhibiteurs de KRAS et des inhibiteurs tyrosine kinase anti-angiogéniques (TKI) dans plusieurs types de tumeurs.
Le FTI de prochaine génération de la société, KO-2806, montre une puissance supérieure et des propriétés améliorées par rapport aux candidats de première génération. Des études précliniques ont révélé que les FTI suppriment efficacement la signalisation mTOR et ont le potentiel d’impacter plus de 200 000 patients incidentels par an aux États‑Unis dans divers cancers, notamment le carcinome rénal, les tumeurs neuroendocrines, le NSCLC, le cancer colorectal et le cancer du sein.
Des données cliniques préliminaires sur KO-2806 seront présentées lors du Congrès ESMO 2025 en octobre, avec trois présentations prévues.
Kura Oncology (NASDAQ:KURA) veranstaltete eine Analysten-/Investorenveranstaltung, bei der präklinische Daten zu ihrem Farnesyltransferase-Inhibitor (FTI) Programm vorgestellt wurden, wobei KO-2806 (Darlifarnib) im Fokus stand. Die Daten zeigen das Potenzial von FTIs, Resistenzen gegen Medikamente zu überwinden, wenn sie mit PI3Kα-Inhibitoren, KRAS-Inhibitoren und antiangiogenen Tyrosinkinaseinhibitoren (TKIs) in mehreren Tumortypen kombiniert werden.
Das Next-Generation-FTI KO-2806 weist im Vergleich zu Kandidaten der ersten Generation überlegene Potenz und verbesserte Eigenschaften auf. Präklinische Studien zeigten, dass FTIs die mTOR-Signalgebung effektiv unterdrücken und das Potenzial haben, über 200.000 incident patients pro Jahr in den USA in verschiedenen Krebsarten wie Nierenzellkarzinom, neuroendokrine Tumoren, NSCLC, Darm-/Kolorektalkrebs und Brustkrebs zu beeinflussen.
Preklinische Daten zu KO-2806 werden beim ESMO Congress 2025 im Oktober präsentiert, mit drei geplanten Vorträgen.
Kura Oncology (NASDAQ:KURA) عقدت حدثاً للمحللين/المستثمرين عرضت فيه بيانات ما قبل السريرية حول مثبط فِرانسل ترانسبَز (FTI) الخاص بها، مع إبراز KO-2806 (darlifarnib) بشكل خاص. تبين البيانات إمكانات FTIs في التغلب على مقاومة الدواء عند دمجها مع مثبطات PI3Kα، ومثبطات KRAS، ومثبطات كيناز النيوكليوتيدات التيروزينية المضادة لتكوٌّن الأوعية في عدة أنواع من الأورام.
يظهر FTI من الجيل التالي KO-2806 فعالية أعلى وخصائص معززة مقارنةً بمرشحي الجيل الأول. أظهرت الدراسات قبل السريرية أن FTIs تقمع إشارات mTOR بفاعلية ولديها القدرة على التأثير على أكثر من 200,000 مريض حاد سنوياً في الولايات المتحدة عبر أنواع سرطانات بما في ذلك سرطان خلايا الكلية، والأورام العصبية الغدية، NSCLC، سرطان القولون والمستقيم، وسرطان الثدي.
سيتم تقديم بيانات سريرية خام لـ KO-2806 في مؤتمر ESMO Congress 2025 في أكتوبر، مع ثلاث عروض مقررة.
Kura Oncology (NASDAQ:KURA) 主办了一场分析师/投资者活动，展示其法尼基转移酶抑制剂（FTI）计划的前临床数据，特别强调 KO-2806（达利法纳比）。数据表明，FTI 与 PI3Kα 抑制剂、KRAS 抑制剂及抗血管生成的酪氨酸激酶抑制剂（TKI）联用，在多种肿瘤中具有克服药物耐药性的潜力。
公司下一代 FTI KO-2806 相较于第一代候选药物，显示出 更高的效力和改进的特性。前临床研究显示，FTI 能有效抑制 mTOR 信号传导，并且在美国多种癌症类型中，潜在影响 每年超过 200,000 例新发患者，包括肾细胞癌、神经内分泌肿瘤、NSCLC、结直肠癌和乳腺癌。
KO-2806 的初步临床数据将于 2025 年 10 月在 ESMO Congress 2025 上发表，计划有三场演讲。
- Preclinical data shows KO-2806 successfully overcomes drug resistance mechanisms
- Potential to impact over 200,000 incident patients annually in the U.S.
- KO-2806 demonstrates superior potency and enhanced properties compared to first-generation FTIs
- Broad applicability across multiple major cancer types and treatment combinations
- Only preclinical data available currently, pending clinical validation
- Clinical efficacy and safety data yet to be demonstrated in upcoming ESMO presentations
Insights
Kura's FTI darlifarnib shows promising preclinical results in overcoming cancer treatment resistance, with clinical data forthcoming at ESMO.
Kura Oncology's preclinical data presentation for KO-2806 (darlifarnib) represents an innovative approach to a critical challenge in oncology treatment. The data demonstrates that their farnesyl transferase inhibitor (FTI) can potentially overcome resistance mechanisms when combined with three major classes of targeted therapies: PI3Kα inhibitors, KRAS inhibitors, and antiangiogenic tyrosine kinase inhibitors (TKIs).
The mechanistic insight behind these combinations is particularly compelling. By targeting mTOR signaling—a clinically validated pathway—Kura's FTI appears to address both innate and adaptive resistance that limits long-term efficacy of these targeted therapies as monotherapies. The preclinical models show KO-2806 can even re-sensitize tumors to KRAS inhibitors in relapsed settings, which is noteworthy given the historical challenges in targeting KRAS mutations effectively.
What sets KO-2806 apart is its deliberate optimization over first-generation FTIs, with improved potency, pharmacokinetics, and physicochemical properties. The broad applicability across multiple cancer types—including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and breast cancer—suggests potential for wide clinical impact, possibly benefiting
While these preclinical results are promising, investors should note that the true clinical significance remains to be established. The upcoming preliminary clinical data presentation at ESMO 2025 next month will be crucial in validating whether these preclinical findings translate to human patients. The company's scheduled three presentations at ESMO suggests confidence in their data package, but prudent evaluation requires awaiting these clinical results.
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)
Preliminary clinical data and KO-2806 development plans to be presented in October 2025 in conjunction with the ESMO Congress 2025
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today is hosting the first of two analyst/investor events focused on its farnesyl transferase inhibitor (FTI) program. The session features compelling preclinical data illustrating the potential of FTIs to address a common resistance pathway, thereby enhancing the anti-tumor activity of PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) across a range of diverse tumor types. These findings, drawn from Kura’s pioneering research on FTI mechanisms, offer important context to interpret the preliminary clinical data to be presented next month at the ESMO Congress 2025.
“Innovation in cancer therapy demands not just new drugs, but smarter combinations to confront resistance head-on,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Today's preclinical presentations underscore the transformative potential of KO-2806 – also known as darlifarnib – as a versatile combination therapy to major classes of precision medicines, paving the way for our upcoming presentations of its first, preliminary clinical data at ESMO 2025 next month.”
Topics discussed during today’s event include:
- Overcoming Resistance: Innate and adaptive resistance mechanisms can significantly limit the long-term efficacy of monotherapy with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs), underscoring the need for combination therapies.
- Pioneering FTI Innovation: Kura has pioneered the discovery and development of farnesyl transferase inhibition and the targeting of mTOR – a clinically validated target – to overcome drug resistance and amplify the impact of targeted oncology therapeutics when paired with an FTI.
- KO-2806, A Next-Generation FTI: Also known as darlifarnib, KO-2806 is Kura’s optimized, next-generation FTI, which was designed to provide superior potency, pharmacokinetics and physicochemical properties compared to first-generation candidates. Preclinical studies support the use of KO-2806 in combination with other agents to target pathways of resistance across a range of large indications.
- Robust Preclinical Activity: In a broad panel of genetically-defined, in vivo tumor models, FTIs potently suppress mTOR signaling, driving enhanced anti-tumor activity when combined with antiangiogenic TKIs, PI3Kα inhibitors and KRAS inhibitors.
- Class-Wide Applicability: Preclinical results with multiple agents from each targeted therapy class indicate broad mechanistic overlap, suggesting KO-2806’s potential extends across these classes.
- Re-Sensitization in Relapsed Models: In preclinical non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) models, KO-2806 re-sensitizes tumors to both mutant-selective or pan-KRAS inhibitors, restoring responsiveness in these models of relapsed settings.
- Upcoming Clinical Milestones: In advance of its three presentations of FTI clinical data at the ESMO 2025 Congress, Kura reviewed the rationale, design and objectives of its ongoing FTI Phase 1 trials.
- Expansive Patient Opportunity: KO-2806 combinations with standard-of-care agents could reach a substantial patient population. Combining with cabozantinib or other TKIs positions KO-2806 to address critical gaps in the treatment of renal cell carcinoma (RCC) and neuroendocrine tumors (NET). Extending to KRAS- and PI3Kα-mutant cancers in NSCLC, CRC, breast cancer and beyond, KO-2806 has the potential to impact more than 200,000 incident patients in the U.S. annually.
Today’s event will be held at 1:30 p.m. PT / 4:30 p.m. ET.
Kura plans to host a second event on October 18, 2025, at 10:30 a.m. PT / 1:30 p.m. ET to review clinical data from Kura’s three scheduled presentations at the European Society of Medical Oncology (ESMO) Congress 2025.
A live webcast and archived replay of each event will be available on the Events page in the Investors section of Kura’s website.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
What is KO-2806 (darlifarnib) and how does it work in cancer treatment?
What types of cancer could Kura Oncology's KO-2806 potentially treat?
When will Kura Oncology (KURA) present clinical data for KO-2806?
How many patients could potentially benefit from KO-2806 treatment?
What are the key advantages of Kura Oncology's KO-2806 over first-generation FTIs?
